What are your top takeaways in Gynecologic Cancers from ASCO 2023?

Gynecologic oncology research was strong at ASCO 2023. Results of the following 3 pivotal studies are practice changing.

1. Marie Plante, MD: SHAPE trial: This non-inferiority CCTG (Canadian Cancer Trials Troup) trial enrolled 700 patients with low-risk squamous cell carcinoma, adenocarcinoma or adenos...

In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.

Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinde...

The Gynecological Oncology section at ASCO was slightly disappointing with some notable negative trials intermixed with some positive ones.

By tumor site, most of the important papers were from Cervix cancer

1) The SHAPE study led by the Canadian intergroup and Dr. Plante: An international randomize...

1. KEYNOTE-826 survival data - such important information for patients and their families. This justifies a 4 drug regimen with maintenance.
2. DUO-O - interesting to look at HRP group and consider how to improve progression-free survival in this difficult to treat group.
3. MIRASOL - for biomarker positiv...